Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Clinical trial NCT01643603 · TERMINATED
Trial details
- NCT number
- NCT01643603
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-05-01
- Primary completion
- 2018-10-09
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.